Hot products 
-
Rabbit Anti-CCL5 Recombinant Antibody (R0437) (CBMAB-R0437-CN)
-
Mouse Anti-BIRC5 Recombinant Antibody (6E4) (CBMAB-CP2646-LY)
-
Mouse Anti-BANF1 Recombinant Antibody (3F10-4G12) (CBMAB-A0707-LY)
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-BAD (Phospho-Ser136) Recombinant Antibody (CBYY-0138) (CBMAB-0139-YY)
-
Mouse Anti-Acetyl SMC3 (K105/K106) Recombinant Antibody (V2-634053) (CBMAB-AP052LY)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Human Anti-SARS-CoV-2 S1 Monoclonal Antibody (CBFYR-0120) (CBMAB-R0120-FY)
-
Mouse Anti-HTLV-1 gp46 Recombinant Antibody (CBMW-H1006) (CBMAB-V208-1154-FY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Mouse Anti-CD24 Recombinant Antibody (SN3) (CBMAB-C1037-CQ)
-
Mouse Anti-BAX Recombinant Antibody (CBYY-0216) (CBMAB-0217-YY)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...



